Serum-soluble Interleukin-2 Receptor Levels in Various Disoders

• Published in: Japanese Journal of National Medical Services Vol. 48; no. 12; pp. 1016 - 1021
• Main Authors: IHARA Akihiro, FURUBAYASHI Takayasu, TOMINAGA Nobuhiko, KAWAMOTO Toshiharu, YOSHINO Koji, KOBAYASHI Yasuki, ISHIKAWA Katsunori, SAITO Toyohiko, MATSUDA Masami, YAMAMOTO Toshiyuki, KATAYAMA Shoichi
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of National Medical Services 1994; 一般社団法人 国立医療学会
• Subjects: aortic aneurysm; autoimmune disorder; hematopoietic malignancy; soluble interleukin-2 receptor; 可溶性インターロイキン2受容体; 大動脈瘤; 自己免疫疾患; 血液悪性疾患
• ISSN: 0021-1699; 1884-8729
• DOI: 10.11261/iryo1946.48.1016

The levels of soluble interleukin-2 receptors (sIL-2R) were determined in the sera of 59 patients with hematopoietic malignancies, 36 patients with autoimmune disorders and 16 patients with aortic aneurysm. Serum samples from 39 healthy individuals were used as controls.The mean serum levels of sIL-2R were extremely high at the time of diagnosis in five patients with malignant reticulosis, one patient with large granular lymphocyte (LGL) leukemia (CD3- CD16+) and one patient with adult T-cell leukemia (ATL) [53, 268.70±49, 365.60 vs 397.90±131.57U/ml in controls (mean±SD)]. In 18 patients with malignant lymphoma, the mean sIL-2R level was significantly higher than controls and the level remarkably decreased after chemotherapy.The mean serum sIL-2R levels in seven patients with chronic myelocytic leukemia (CML) in remission by interferon-α, 12 patients with paraproteinemia, six patients with myelodysplastic syndrome (MDS) and 16 patients with aortic aneurysm were significantly higher than controls. In seven of eight patients with AML, the serum sIL-2R levels were normal. The mean sIL-2R levels at the time of partial or complete remission in 17 patients with SLE and rheumatoid arthritis, and in 19 patients with ITP were significantly higher than controls.We conclude that the serum sIL-2R can serve not only as a valuable tumor marker for monitoring patient's treatment, but also as atherosclerotic or immunological markers. In our case of LGL leukemia who showed extremely high sIL-2R (α chain) levels, the source of sIL-2R in serum might be released by normal T-cells activated by LGL leukemic cells. 可溶性インターロイキン-2レセプター(sIL-2R)を血液悪性疾患59例(平均年齢59歳), 自己免疫疾患36例(平均48歳), 大動脈瘤16例(平均69歳)に健常人39例(平均33歳)をコントロールとして測定した. 健常人のsIL-2Rの平均値+1 SDは397.90±131.57U/mlであった. 治療前の悪性細網症4例, NK型のLGL白血病1例, ATL 1例は平均53,268.70±49,365.60U/mlと著明高値を示し(特にLGL白血病1例は135,000U/mlと著明高値), 治療後の悪性細網症5例は1,983.60±3,377.85U/mlと有意な低下を示した. 悪性リンパ腫(非ホジキンリンパ腫14例, ホジキン病4例)の治療前は5,114.50±4,580.46U/mlで治療後は有意な低下を示した. 寛解中のCMIL 7例の平均値は834U/ml, 多発性骨髄腫12例とマクログロブリン血症1例は1,033U/ml, MDS 6例は981U/ml, SLE, RA 17例は治療中であり1,552U/ml, ITP 19例は734U/mlでコントロールに比べ有意な高値を示した. AML 8例中7例は正常範囲であった. 大動脈瘤16例は1,303.50±751.81U/mlで正常人に比べ有意な(p<0.01)高値を示した.sIL-2Rは, AMLを除く血液悪性疾患と自己免疫疾患で有意な高値を示し, 治療の指標になると考えられた. 本来細胞膜表面にIL-2R β鎖のみ発現するといわれるNK型LGL白血病にsIL-2R(α鎖)が著明高値を示したことは, sIL-2Rの由来が腫瘍細胞からではなく, 正常の活性化T細胞から放出された可能性を示唆した. 大動脈瘤でも高値を示したことからIL-2の動脈硬化への関与が示唆された.